Haemonetics Corporation (HAE) Institutional Ownership & Insider Trading

329 institutions reported holding Haemonetics Corporation shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 1 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

HAEHaemonetics CorporationFollow HAE — free

Medical Devices · Healthcare

—

Price chart with a free account

Market cap: 5.4B
P/E TTM: 57.3
Dividend yield: —
52-week: —
Next earnings: 4 Nov, in 11 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

329 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +4.3%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	329	50	+4.3%	100	45	114	40
Mar 26	323	47	-9.4%	112	45	103	51
Dec 25	327	52	+0.1%	92	60	119	34
Sep 25	293	52	-5.9%	89	43	109	45
Jun 25	295	54	+0.1%	109	29	93	40
Mar 25	312	54	-3.5%	113	44	92	38
Dec 24	305	57	+1.0%	110	33	85	36
Sep 24	301	55	-1.2%	93	34	94	47

Haemonetics Corporation — questions

Who owns Haemonetics Corporation stock?: 329 institutions reported Haemonetics Corporation shares in 13F filings for the quarter ended 2026-06-30. The largest: BlackRock, Inc. (13.0%), NEUBERGER BERMAN GROUP LLC (9.2%), VANGUARD PORTFOLIO MANAGEMENT LLC (5.6%).
Are Haemonetics Corporation insiders buying or selling?: 1 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Haemonetics Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.